Skip to main content
. 2000 Apr;129(7):1355–1364. doi: 10.1038/sj.bjp.0703189

Figure 2.

Figure 2

Effect of NSD-1015 (25 mg kg−1 i.p.) pretreatment on plasma levels of (A) L-DOPA and 3-OMD, and (B) dopamine, and DOPAC, following the administration of L-DOPA (12.5 mg kg−1 s.c.). NSD-1015 was administered 45 min prior to L-DOPA. A blood sample was taken after a further 45 min following L-DOPA treatment. The results are shown as mean±s.e.mean for six animals. NSD-1015 25 mg kg−1 significantly increased plasma L-DOPA and 3-OMD concentrations (**P<0.01) vs saline vehicle and significantly decreased plasma dopamine and DOPAC (*P<0.05 and **P<0.01 respectively) vs saline vehicle.